Maquirriain Javier, Kokalj Antonio
High Performance National Sports Center, Buenos Aires, Argentina.
Georgian Med News. 2013 Sep(222):36-43.
Tendinopathies are a major cause of disability in the athletic population; the main purpose of the treatment of these injuries is to reduce pain and improve function promptly. The objective of this randomized, active comparator controlled, blinded study was to evaluate etoricoxib efficacy in pain control and leg stiffness in athletes suffering acute unilateral Achilles tendinopathy. Fifty-six eligible male athletes (mean age 37.5 ± 11.0 y) suffering acute Achilles tendinopathy were randomized to receive either etoricoxib 120 mg oral once daily (n=28) or diclofenac 100 mg oral once daily (n=28). Pain (100-mm visual analogue scale-VAS), analgesic effect (percentage of 100-mm VAS reduction), satisfaction with pain management (PGART), and leg stiffness (LSR) were evaluated after one week of anti-inflammatory treatment. Over the 7-day treatment period, both etoricoxib and diclofenac provided significantly relief of Achilles tendon pain compared to that experienced at baseline (mean VAS 26.7 ± 2.2 and 56.4 ± 1.8, respectively; p<.001). Analgesic effect averaged 53.7 ± 38.1% (etoricoxib= 56.4% and diclofenac 50.6%, p=0.64). Patients referred high level of satisfaction with anti-inflammatory treatment (PGART = 2.0 ± 1.3), while leg stiffness showed a significant improvement after one-week therapy (LSR 0.89 ± 0.1 vs. 0.95 ± 0.1; p=0.038). PGART and LSR values within etoricoxib and diclofenac groups were not significant (p=0.46, and p=0.37, respectively). Both drugs were generally well tolerated; patients receiving etoricoxib reported significantly less side effects than those in the diclofenac group (0% and 14,2%, respectively, p=0.037). Etoricoxib is clinically effective in treatment of acute Achilles tendinopathy providing a magnitude of effect comparable to that of diclofenac with fewer side effects. Effective control of tendon pain in the acute phase of such sports-related injuries may be helpful to reduce morbidity and improve capabilities associated with high performance like leg stiffness.
肌腱病是运动员致残的主要原因;治疗这些损伤的主要目的是迅速减轻疼痛并改善功能。这项随机、活性对照、双盲研究的目的是评估依托考昔对急性单侧跟腱肌腱病运动员的疼痛控制和腿部僵硬的疗效。56名符合条件的患有急性跟腱肌腱病的男性运动员(平均年龄37.5±11.0岁)被随机分为两组,一组每天口服一次120毫克依托考昔(n=28),另一组每天口服一次100毫克双氯芬酸(n=28)。在抗炎治疗一周后,评估疼痛(100毫米视觉模拟量表-VAS)、镇痛效果(100毫米VAS降低的百分比)、对疼痛管理的满意度(PGART)和腿部僵硬程度(LSR)。在7天的治疗期内,与基线时相比,依托考昔和双氯芬酸均能显著缓解跟腱疼痛(平均VAS分别为26.7±2.2和56.4±1.8;p<0.001)。镇痛效果平均为53.7±38.1%(依托考昔=56.4%,双氯芬酸=50.6%,p=0.64)。患者对抗炎治疗的满意度较高(PGART=2.0±1.3),而腿部僵硬程度在一周治疗后有显著改善(LSR 0.89±0.1对0.95±0.1;p=0.038)。依托考昔组和双氯芬酸组的PGART和LSR值无显著差异(分别为p=0.46和p=0.37)。两种药物总体耐受性良好;接受依托考昔治疗的患者报告的副作用明显少于双氯芬酸组(分别为0%和14.2%,p=0.037)。依托考昔在治疗急性跟腱肌腱病方面临床有效,其疗效与双氯芬酸相当,但副作用更少。有效控制此类运动相关损伤急性期的肌腱疼痛可能有助于降低发病率,并改善与腿部僵硬等高性能相关的能力。